Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 3/20 | 0.58 |
| ▸ | EGFR | P00533 | 2/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
| ▸ | CTRC | Q99895 | 1/20 | 0.54 |
| ▸ | EEF2K | O00418 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366145 | 0.95 | EGFR (0.53) | ERBB2EGFRIGF1RCTRCEEF2K | |
| SCHEMBL5370420 | 0.93 | ERBB2 (0.51) | ERBB2EGFRIGF1RCTRCEEF2K | |
| SCHEMBL5364368 | 0.92 | ERBB2 (0.50) | ERBB2EGFRIGF1RCTRCEEF2K | |
| SCHEMBL5367712 | 0.88 | ERBB2 (0.47) | ERBB2EGFRIGF1RCTRCEEF2K | |
| SCHEMBL5365551 | 0.86 | ERBB2 (0.60) | ERBB2EGFRIGF1RCTRCSIRT1 | |
| SCHEMBL6689435 | 0.84 | ERBB2 (0.67) | ERBB2EGFRIGF1RCTRCEEF2K | |
| SCHEMBL5368253 | 0.84 | ERBB2 (0.67) | ERBB2EGFRIGF1RCTRCSIRT1 | |
| SCHEMBL5369391 | 0.84 | EGFR (0.41) | ERBB2EGFRIGF1RCTRCGAA | |
| SCHEMBL5362076 | 0.84 | LRRK2 (0.52) | EGFREEF2KSRCGAASIRT1 | |
| SCHEMBL7134818 | 0.83 | MAP1LC3B (0.60) | EGFRSIRT1SIRT2SIRT3MAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | ERBB2 19/4885EGFR 286/4885IGF1R 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.